Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Belantamab

Various toxicities following off-label use: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Walker M, et al. Outcomes from real world use of Belantamab at the Beatson Cancer Centre in relapsed/ refractory myeloma. British Journal of Haematology 201 (Suppl. 1): 151 (plus poster) abstr. BSH23-EP159, Apr 2023. Available from: URL: http://doi.org/10.1111/bjh.18721 [abstract] Walker M, et al. Outcomes from real world use of Belantamab at the Beatson Cancer Centre in relapsed/ refractory myeloma. British Journal of Haematology 201 (Suppl. 1): 151 (plus poster) abstr. BSH23-EP159, Apr 2023. Available from: URL: http://​doi.​org/​10.​1111/​bjh.​18721 [abstract]
Metadaten
Titel
Belantamab
Various toxicities following off-label use: 3 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41353-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Azathioprine

Case report

Tozinameran

Case report

Multiple drugs

Case report

Multiple drugs